Supernus and Indivior Announce All-Stock Merger to Form Diversified CNS Biopharmaceutical Company
Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Inc. (NYSE: INDV), both focused on central nervous system treatments, have agreed to merge in an all-stock transaction structured as a tax-free merger of equals. The combined company aims to create a more diversified biopharmaceutical entity within the CNS sector. Following the announcement, Supernus shares surged 22%, while Indivior stock climbed approximately 10%. Under the terms of the deal, Supernus shareholders will receive 1.5401 common shares of the new combined company for each share they own. The merger is expected to leverage both companies' strengths in CNS therapies and expand their product portfolios through a broader range of treatments. The transaction highlights strategic consolidation within the pharmaceutical industry as firms seek scale, diversification, and operational efficiencies.
Topics: central_nervous_system_drugs pharmaceuticals stock_movement